|
US2021077792A1
|
|
Systems and methods for selectively occluding the superior vena cava for treating heart conditions
|
|
WO2021071868A1
|
|
Systems and methods for determining tissue inflammation levels
|
|
WO2021021593A1
|
|
Adoptive transfer of plasmacytoid cells to prevent or treat hair loss
|
|
WO2020232023A1
|
|
Systems and methods for accessing a renal capsule for diagnostic and therapeutic purposes
|
|
WO2020227463A1
|
|
Objective assessment of joint damage
|
|
WO2020185996A1
|
|
Methods of treating acute coronary syndromes
|
|
WO2020154375A1
|
|
Methods and compositions for the treatment and prevention of ocular diseases and conditions
|
|
WO2020097428A1
|
|
Systems and methods for left ventricular unloading in treating myocardial infarction
|
|
WO2020123019A1
|
|
Decision support device
|
|
WO2020072513A1
|
|
Systems and methods for sensing and correcting electrical activity of nerve tissue
|
|
WO2020061143A1
|
|
Systems and methods for left ventricular unloading in treating myocardial infarction
|
|
WO2020006367A1
|
|
Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions
|
|
WO2020006210A1
|
|
Pyridopyrimidine compounds and methods of their use
|
|
WO2019236750A2
|
|
Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders
|
|
WO2019236754A1
|
|
Compounds and methods for the treatment of autism spectrum disorder and other neurological or psychiatric disorders
|
|
WO2019212911A1
|
|
System for detecting micro-neuromas and methods of use thereof
|
|
SG11202006039TA
|
|
Systems and methods for left ventricular unloading in treating myocardial infarction
|
|
US2019209003A1
|
|
Systems and methods for controlled dichoptic viewing
|
|
US2020277382A1
|
|
Bispecific antibody constructs and methods of use
|
|
US2019126014A1
|
|
Systems and methods for selectively occluding the superior vena cava for treating heart conditions
|
